SCHEMBL27802492

SCHEMBL27802492

NN(C(=O)O)c1nc2ccccc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
NPC1 O15118 6/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
ALOX15 P16050 2/20 0.54
TSHR P16473 2/20 0.54
ALDH1A1 P00352 6/20 0.47
HPGD P15428 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
PKM P14618 1/20 0.45
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10697633 0.86 RAB9A (0.69) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL27800721 0.83 ALOX15 (0.54) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL24555308 0.81 TP53 (0.49) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL11613440 0.81 RAB9A (0.59) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL2939270 0.80 NPC1 (0.75) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL24555364 0.79 NPC1 (0.52) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL16851761 0.79 NPC1 (0.51) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL18596655 0.79 NPC1 (0.49) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL8076003 0.79 SMN1; SMN2 (0.56) RAB9ASMN1; SMN2NPC1LMNATP53
SCHEMBL15722690 0.78 NPC1 (0.50) RAB9ASMN1; SMN2NPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101959516-B Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2013-05-08 CN disclosed
CN-101959516-A Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2011-01-26 CN disclosed